22
Sat, Jul
44 New Articles

Schoenherr Advises Roche on Acquisition of MySugr

Schoenherr Advises Roche on Acquisition of MySugr

Austria
Typography

Schoenherr has advised the Roche Group on its acquisition of all shares of mySugr GmbH.

Founded in 2012, mySugr specializes in all-around care for people with diabetes. Its apps and services combine diabetes coaching, therapy management, unlimited test-strips, automated data tracking, and integration with a growing number of medical devices. Schoenherr describes mySugr, which has over one million users globally, as "one of the leading mobile diabetes platforms," and reports that it "will become an integral part of Roche’s new patient-centered digital health services platform in diabetes care." Early investors in mySugr included business angel Hansi Hansmann, iSeed Ventures, and the Roche Venture Fund.

Schoenherr describes Roche as "a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives," and reports that "the combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics."

"Healthcare is a growing and increasingly important sector on which Schoenherr places a lot of emphasis," stated Schoenherr Partner Florian Kusznier, who headed the firm's team on the deal along with Attorney at Law Clemens Rainer. "As the partner responsible for this industry within our firm, I was particularly excited to support Roche on this transaction."

In addition to Kusznier and Rainer, "the Schoenherr team advising Roche consisted of Partner Volker Weiss, Counsel Gunther Leissler, Attorneys at Law Veronika Wolfbauer, Dominik Hofmarcher, Julia Wasserburger, and Mario Perl, and Associates Marco Thorbauer, Teresa Waidmann, Arzu-Sema Cakmak, Christopher Junger, Sascha Smets.

Our Latest Issue